Premas Biotech of India has collaborated with Ormed Pharmaceuticals Inc. to develop an oral COVID-19 vaccine candidate, which has shown efficacy after a single dose.
Preliminary testing of this vaccine candidate in animals has shown that this vaccine has produced the desired antibodies. However, this product / vaccine has not yet been tested on humans.
According to this company, it completely depends on what kind of results the current tests give. If they are successful, these vaccine candidates may be ready for human trials within the next three months.
This clinical study is expected to begin in the second quarter of the year 2021.
The nascent COVID-19 vaccine candidate is a protein-based VLP (a virus-like particle) vaccine candidate.
• It is capable of causing "triple protection" against the SARS CoV-2 virus. It can target spike, membrane and envelope proteins of the corona virus. Most other vaccines are based on the Spike (S) protein.
• It promotes systemic immunity through immunoglobulin G (IgG), the most common antibody in blood and body fluids that protects against viral infection and immunoglobulin A (IgA).
Oravax stated in a statement that, this vaccine candidate is safe, effective and can be well tolerated from normal to high doses and produces high titres of neutralizing antibodies.
The company also stated that, the protein-based VLP (a virus-like particle) vaccine has been manufactured using Candidate Premas' proprietary D-Crypt ™ platform, which is highly scalable / scalable and can be mass-produced. Can.
